Mako Surgical Corp. - Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Expires: January 31, 2008 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

BRUNK GERALD A

2. Date of Event Requiring Statement (MM/DD/YYYY) 2/14/2008

3. Issuer Name and Ticker or Trading Symbol

MAKO Surgical Corp. [MAKO]

(Last) (First) (Middle)

C/O LUMIRA CAPITAL CORP., 245 FIRST STREET, SUITE 1800

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director ___ X ___ 10% Owner
_____ Officer (give title below) _____ Other (specify below)

(Street)

CAMBRIDGE, MA 02142

(City) (State) (Zip)

5. If Amendment, Date Original Filed (MM/DD/YYYY)

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Series B Convertible Preferred Stock	7/14/2005	⁽¹⁾	Common Stock	770358 ⁽¹⁾	⁽¹⁾	I	By Lumira Capital I Limited Partnership ⁽²⁾
Series B Convertible Preferred Stock	7/14/2005	⁽¹⁾	Common Stock	271412 ⁽¹⁾	⁽¹⁾	I	By MDS Life Sciences Technology Fund II Quebec Limited Partnership ⁽³⁾
Series B Convertible Preferred Stock	7/14/2005	⁽¹⁾	Common Stock	208354 ⁽¹⁾	⁽¹⁾	I	By MLII Co-Investment Fund NC Limited Partneship ⁽⁴⁾
Series C Convertible Preferred Stock	2/6/2007	⁽¹⁾	Common Stock	274830 ⁽¹⁾	⁽¹⁾	I	By Lumira Capital I Limited Partnership ⁽²⁾
Series C Convertible Preferred Stock	2/6/2007	⁽¹⁾	Common Stock	96828 ⁽¹⁾	⁽¹⁾	I	By MDS Life Sciences Technology Fund II Quebec Limited Partnership ⁽³⁾
Series C Convertible Preferred Stock	2/6/2007	⁽¹⁾	Common Stock	74331 ⁽¹⁾	⁽¹⁾	I	By MLII Co-Investment Fund NC Limited Partneship ⁽⁴⁾

Explanation of Responses:
( 1)	The convertible preferred stock has no expiration date. As a result of a one-for-3.03 reverse split of MAKO Surgical Corp. common stock, each share of convertible preferred stock is convertible into .330033 of a share of common stock. Accordingly, upon the closing of the issuer's initial public offering, the convertible preferred stock will convert into the number of shares of common stock set forth in Column 3.
( 2)	Lumira Capital Management Corp. ("Lumira Management"), a subsidiary of Lumira Capital Corp., is a party to a management agreement with Lumira Capital I Limited Partnership (formerly known as MDS Life Sciences Technology Fund II NC Limited Partnership). The reporting person is the Senior Vice President/Managing Director of Lumira Capital Corp., but he disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
( 3)	Lumira Management provides services to MDS Life Sciences Technology Fund II Quebec Limited Partnership. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
( 4)	Lumira Management provides services to MLII Co-Investment Fund NC Limited Partnership. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

Remarks:
Exhibit List
Exhibit 24 - Power of Attorney

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
BRUNK GERALD A C/O LUMIRA CAPITAL CORP. 245 FIRST STREET, SUITE 1800 CAMBRIDGE, MA 02142	X	X

Signatures
/s/Menashe R. Frank, attorney in fact		2/14/2008
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.